HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.

Abstract
The acquisition of integrin-directed metastasis-associated (ID-MA) phenotypes by Triple-Negative Breast Cancer (TNBC) cells is caused by an upregulation of the Wnt-beta-catenin pathway (WP). We reported that WP is one of the salient genetic features of TNBC. RAC-GTPases, small G-proteins which transduce signals from cell surface proteins including integrins, have been implicated in tumorigenesis and metastasis by their role in essential cellular functions like motility. The collective percentage of alteration(s) in RAC1 in ER+ve BC was lower as compared to ER-ve BC (35% vs 57%) (brca/tcga/pub2015). High expression of RAC1 was associated with poor outcome for RFS with HR=1.48 [CI: 1.15-1.9] p=0.0019 in the Hungarian ER-veBC cohort. Here we examined how WP signals are transduced via RAC1 in the context of ID-MA phenotypes in TNBC. Using pharmacological agents (sulindac sulfide), genetic tools (beta-catenin siRNA), WP modulators (Wnt-C59, XAV939), RAC1 inhibitors (NSC23766, W56) and WP stimulations (LWnt3ACM, Wnt3A recombinant) in a panel of 6-7 TNBC cell lines, we studied fibronectin-directed (1) migration, (2) matrigel invasion, (3) RAC1 and Cdc42 activation, (4) actin dynamics (confocal microscopy) and (5) podia-parameters. An attenuation of WP, which (a) decreased cellular levels of beta-catenin, as well as its nuclear active-form, (b) decreased fibronectin-induced migration, (c) decreased invasion, (d) altered actin dynamics and (e) decreased podia-parameters was successful in blocking fibronectin-mediated RAC1/Cdc42 activity. Both Wnt-antagonists and RAC1 inhibitors blocked fibronectin-induced RAC1 activation and inhibited the fibronectin-induced ID-MA phenotypes following specific WP stimulation by LWnt3ACM as well as Wnt3A recombinant protein. To test a direct involvement of RAC1-activation in WP-mediated ID-MA phenotypes, we stimulated brain-metastasis specific MDA-MB231BR cells with LWnt3ACM. LWnt3ACM-stimulated fibronectin-directed migration was blocked by RAC1 inhibition in MDA-MB231BR cells. In the light of our previous report that WP upregulation causes ID-MA phenotypes in TNBC tumor cells, here we provide the first mechanism based evidence to demonstrate that WP upregulation signals ID-MA tumor cell phenotypes in a RAC1-GTPase dependent manner involving exchange-factors like TIAM1 and VAV2. Our study demonstrates for the first time that beta-catenin-RAC1 cascade signals integrin-directed metastasis-associated tumor cell phenotypes in TNBC.
AuthorsPradip De, Jennifer H Carlson, Tyler Jepperson, Scooter Willis, Brian Leyland-Jones, Nandini Dey
JournalOncotarget (Oncotarget) Vol. 8 Issue 2 Pg. 3072-3103 (Jan 10 2017) ISSN: 1949-2553 [Electronic] United States
PMID27902969 (Publication Type: Journal Article)
Chemical References
  • Actins
  • Aminoquinolines
  • Biomarkers
  • Fibronectins
  • Integrins
  • NSC 23766
  • Pyrimidines
  • RNA, Small Interfering
  • beta Catenin
  • cdc42 GTP-Binding Protein
  • rac1 GTP-Binding Protein
Topics
  • Actins (metabolism)
  • Aminoquinolines (pharmacology)
  • Biomarkers
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Computational Biology (methods)
  • Databases, Genetic
  • Enzyme Activation (drug effects)
  • Female
  • Fibronectins (metabolism)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Integrins (metabolism)
  • Kaplan-Meier Estimate
  • Neoplasm Metastasis
  • Phenotype
  • Prognosis
  • Protein Transport
  • Pyrimidines (pharmacology)
  • RNA Interference
  • RNA, Small Interfering (genetics)
  • Triple Negative Breast Neoplasms (genetics, metabolism, mortality, pathology)
  • Wnt Signaling Pathway (drug effects)
  • beta Catenin (metabolism)
  • cdc42 GTP-Binding Protein (genetics, metabolism)
  • rac1 GTP-Binding Protein (antagonists & inhibitors, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: